Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Golvatinib |
Synonyms | |
Therapy Description |
Golvatinib (E7050) is a dual kinase inhibitor of c-Met and KDR (VEGFR2), which inhibits cell growth and proliferation (PMID: 25458359). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Golvatinib | E7050|E-7050 | EPHB4 Inhibitor 6 MET Inhibitor 51 VEGFR2 Inhibitor 35 | Golvatinib (E7050) is a dual kinase inhibitor of c-Met (MET) and KDR (VEGFR2), which inhibits cell growth and proliferation (PMID: 25458359, PMID: 25278451). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
Unknown unknown | pancreatic cancer | not applicable | Golvatinib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Golvatinib (E7050) inhibited tumor angiogenesis and tumor growth in xenografts of a VEGF-overexpressing human pancreatic cancer cell line (PMID: 19832844). | 19832844 |
Unknown unknown | Advanced Solid Tumor | not applicable | Golvatinib | Phase I | Actionable | In a Phase I trial, Golvatinib (E7050) demonstrated safety and preliminary efficacy, with stable disease as best overall response in patients with advanced solid tumors (PMID: 25278451). | 25278451 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01433991 | Phase Ib/II | Golvatinib Lenvatinib | E7050 in Combination With E7080 in Subjects With Advanced Solid Tumors (Dose Escalation) and in Subjects With Recurrent Glioblastoma or Unresectable Stage III or Stage IV Melanoma After Prior Systemic Therapy (Expansion Cohort and Phase 2) | Completed | USA | 0 |